Impact of FGFR2/3 activating genomic alterations on response to enfortumab vedotin in metastatic urothelial carcinoma (mUC).

被引：4

作者：

Adib, Elio ^{[1
]}

Jain, Rohit K. ^{[2
]}

Skelton, William Paul ^{[3
]}

Freeman, Dory ^{[1
]}

Curran, Catherine ^{[1
]}

Akl, Elie W. ^{[4
]}

Nassar, Amin ^{[4
]}

Ravi, Praful ^{[1
]}

Mantia, Charlene ^{[1
]}

Merchan, Jaime R. ^{[5
]}

Tan, Winston ^{[6
]}

Plastini, Trisha M. ^{[7
]}

Choueiri, Toni K. ^{[1
,8
]}

Sonpavde, Guru ^{[9
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

[2] Lee Moffitt Canc Ctr, Tampa, FL USA

[3] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[4] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA

[5] Univ Miami, Miami, FL USA

[6] Mayo Clin Hosp, Jacksonville, FL USA

[7] Univ Penn Hlth Syst, Philadelphia, PA USA

[8] Harvard Med Sch, Boston, MA 02115 USA

[9] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 06期

关键词：

D O I：

10.1200/JCO.2021.39.6_suppl.472

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

472

引用

页数：3

共 50 条

[21] FGFR2/3 genomic alterations (GA) in cell-free (cf)DNA from patients (pts) with advanced urothelial carcinoma (aUC)
Kiedrowski, Lesli Ann
Thomas, Roby Antony
Vogelzang, Nicholas J.
Sonpavde, Guru
Gupta, Sumati
Gourdin, Theodore Stewart
Faltas, Bishoy Morris
Nagy, Rebecca
Lanman, Richard B.
Grivas, Petros
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[22] Durable Response After Combination Therapy With Enfortumab Vedotin and Radiotherapy in Metastatic Urothelial Carcinoma: A Report of Two Cases
Ikarashi, Daiki
Kikuchi, Koyo
Takahashi, Kenta
Ariga, Hisanori
Obara, Wataru
CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (12)
[23] Response to immunotherapy, platinum-based chemotherapy or their combination in metastatic urothelial carcinoma (MUC) with or without FGFR-3 alterations: Single cohort experience
Ferrer-Mileo, Laura
Rodriguez, Adela
Gonzalez, Nuria
Orrillo, Mayra
Jimenez, Natalia
Marin-Aguilera, Mercedes
Rodriguez-Carunchio, Leonardo
Prat, Aleix
Mellado, Begona
Reig, Oscar
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[24] Outcomes of patients (pts) with metastatic urothelial carcinoma (mUC) following discontinuation of enfortumab-vedotin (EV): Emergence of a new unmet need.
Curran, Catherine
Pond, Gregory Russell
Kazakova, Vera
Grivas, Petros
Diamantopoulos, Leonidas Nikolaos
Alva, Ajjai Shivaram
Su, Christopher
Jain, Rohit K.
Tandon, Ankita
Zhang, Jingsong
Necchi, Andrea
Marandino, Laura
Merchan, Jaime R.
Plastini, Trisha M.
Sonpavde, Guru
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[25] C-Reactive Protein-Albumin Ratio Predicts Objective Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma
Uchimoto, Taizo
Matsuda, Takuya
Komura, Kazumasa
Fukuokaya, Wataru
Adachi, Takahiro
Hirasawa, Yosuke
Hashimoto, Takeshi
Yoshizawa, Atsuhiko
Saruta, Masanobu
Hashimoto, Mamoru
Higashio, Takuya
Tsuchida, Shuya
Nishimura, Kazuki
Tsujino, Takuya
Nakamura, Ko
Fukushima, Tatsuo
Nishio, Kyosuke
Yamamoto, Shutaro
Iwatani, Kosuke
Urabe, Fumihiko
Mori, Keiichiro
Yanagisawa, Takafumi
Tsuduki, Shunsuke
Takahara, Kiyoshi
Inamoto, Teruo
Miki, Jun
Fujita, Kazutoshi
Kimura, Takahiro
Ohno, Yoshio
Shiroki, Ryoichi
Uemura, Hirotsugu
Azuma, Haruhito
TARGETED ONCOLOGY, 2024, 19 (04) : 635 - 644
[26] Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint Inhibitors
Uchimoto, Taizo
Tsuchida, Shuya
Komura, Kazumasa
Fukuokaya, Wataru
Adachi, Takahiro
Hirasawa, Yosuke
Hashimoto, Takeshi
Yoshizawa, Atsuhiko
Saruta, Masanobu
Hashimoto, Mamoru
Higashio, Takuya
Matsuda, Takuya
Nishimura, Kazuki
Tsujino, Takuya
Nakamura, Ko
Fukushima, Tatsuo
Nishio, Kyosuke
Yamamoto, Shutaro
Iwatani, Kosuke
Urabe, Fumihiko
Mori, Keiichiro
Yanagisawa, Takafumi
Tsuduki, Shunsuke
Takahara, Kiyoshi
Inamoto, Teruo
Miki, Jun
Fujita, Kazutoshi
Kimura, Takahiro
Ohno, Yoshio
Shiroki, Ryoichi
Uemura, Hirotsugu
Azuma, Haruhito
TARGETED ONCOLOGY, 2024, 19 (03) : 401 - 410
[27] COMPARATIVE NARRATIVE REVIEW OF ONCOLOGY VALUE ASSESSMENT FRAMEWORKS: ENFORTUMAB VEDOTIN (EV) FOR TREATMENT OF LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA (LA/MUC)
Ortiz Nunez, A.
Gonzalez Portela
Zozaya, N.
Meco, I
VALUE IN HEALTH, 2023, 26 (12) : S365 - S365
[28] Phase 2 Trial of Enfortumab Vedotin in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma in China
Li, Siming
Shi, Yanxia
Dong, Haiying
Guo, Hongqian
Xie, Yu
Sun, Zhongquan
Zhang, Xiaoping
Kim, Eric
Zhang, Jun
Li, Yue
Xu, Chenming
Kadeerbai, Haishan
Lee, Sue
Gorla, Seema
Guo, Jun
Sheng, Xinan
CANCER MEDICINE, 2024, 13 (21):
[29] Association of circulating tumor (ct)-DNA genomic alterations (GA) with outcomes in metastatic urothelial carcinoma (mUC)
Grivas, Petros
Pond, Gregory Russell
Nagy, Rebecca J.
Barata, Pedro C.
Mendiratta, Prateek
Gopalakrishnan, Dharmesh
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[30] Outcomes with immune checkpoint inhibitor (ICI) therapy in patients with FGFR2/3 alterations in advanced urothelial carcinoma (aUC).
Talukder, Rafee
Bakaloudi, Dimitra Rafailia
Makrakis, Dimitrios
Tripathi, Nishita
Agarwal, Neeraj
Jindal, Tanya
Koshkin, Vadim S.
Johnson, Jeffrey
Zakharia, Yousef
Brown, Jason
Rey-Cardenas, Macarena
Castellano, Daniel
Alva, Ajjai Shivaram
Zakopoulou, Roubini
Korolewicz, James
Drakaki, Alexandra
Barata, Pedro C.
Grivas, Petros
Khaki, Ali Raza
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41

← 1 2 3 4 5 →